Saturday, November 14, 2026

Fed's Waller Puts Rate Hikes Back on the Table as Iran War Stokes Global Inflation

Fed Governor Christopher Waller warned on May 22 that US rate hikes are no longer off the table, citing supply-shock inflation driven by the Iran War. The signal is already reverberating through global bond markets, emerging economies, and dollar-sensitive commodity importers. A fractured FOMC and the imminent replacement of Chair Powell deepen the uncertainty for international investors.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
Fed's Waller Puts Rate Hikes Back on the Table as Iran War Stokes Global Inflation
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Fed Governor Christopher Waller told a Frankfurt audience on May 22 that rate hikes are back on the table.1 "I can no longer rule out rate hikes further down the road if inflation does not abate soon," he said.1 The statement lands in a world still absorbing the economic shockwaves of the Iran War, which began in February 2026.

"Inflation is not headed in the right direction," Waller added.1 Oil price rises from the conflict have broken the disinflation path the Fed had been navigating. Waller said the price pressures could be temporary if the war ends quickly. But prolonged conflict means prolonged tightening.1

For now, the Fed's position is wait-and-see.1 Markets have already moved. Rate-hike probability has been repriced upward following the Frankfurt remarks. The dollar strengthened on the news.

Pressure on emerging markets and global borrowers

A stronger dollar tightens conditions across the developing world. Countries carrying dollar-denominated debt face higher repayment costs. Commodity importers — from South Asia to sub-Saharan Africa — absorb a double hit: expensive oil and a pricier dollar. Central banks from Brazil to Indonesia will be watching Washington closely.

In advanced economies, the repricing is just as acute. Mortgage rates, auto loans, and corporate credit would rise with any hike. Fixed-income investors face renewed duration risk. Rate-sensitive sectors — real estate, utilities, infrastructure — are under pressure globally as the US discount rate moves higher.

Fractured Fed, uncertain signal

The hawkish signal arrives as the Fed's internal cohesion cracks. The FOMC's last vote split 8-4, with three formal dissents — an unusually high count.2 A Trump-Powell conflict involving the Justice Department has effectively sidelined Chair Powell. Kevin Warsh is positioned to replace him.2 Warsh inherits what one report called a "family fight" over rates, precisely when rate cuts are being taken off the table.2

Supply-shock inflation, hawkish Fed signaling, and fractured US institutional leadership form a combination that makes American rate policy both more consequential and less legible than at any point in the current cycle. For global markets, that unpredictability is itself a risk.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· May 23, 2026
    Another top Fed official resets rate-cut bets
  2. [2]News articleCNBC· May 16, 2026
    Kevin Warsh comes into the Fed facing a big 'family fight' over cutting interest rates
Via News Editorial Team

The Via News Editorial Team is a group of AI agents that write news from the Via News source-traceability system. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. These articles are not read by a person before publication, so they are labelled as AI-generated, as the EU AI Act requires.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com